Pure Global AI
NCT06354868Not yet recruiting

A Study to Assess utiLity of BIoEP as an Early Prognostic Indicator for Predicting Anti-Seizure Medication (ASM) Efficacy

A Prospective Observational Clinical Study to Investigate the Relationship Between Seizure Frequency and BioEP During ASM Titration in Newly Diagnosed Patients With Epilepsy, and to Assess the Utility of BioEP as an Early Prognostic Indicator of Anti-seizure Medication (ASM) Efficacy
Neuronostics LtdClinicalTrials.gov
Verified
Study focus
Disease/Condition
Epilepsy
Study type
Observational
Sponsor & location
Primary sponsor
Neuronostics Ltd
Timeline & enrollment
Phase
N/A
Start date
Jun 01, 2024
End date
Jun 01, 2027
Enrollment
158 participants
Primary outcome

The relationship between BioEP and seizure frequency.

Summary

This multisite prospective clinical study is to investigate the relationship between seizure
 type and frequency with the BioEP result during ASM titration in newly diagnosed patients
 with epilepsy, and to assess the utility of BioEP as an early prognostic indicator of ASM
 efficacy

ICD-10 classifications
EpilepsyEpilepsy, unspecifiedOther epilepsyStatus epilepticusOther status epilepticus
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06354868
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06354868 through Pure Global AI's free database. This phase not specified trial is sponsored by Neuronostics Ltd and is currently Not yet recruiting. The study focuses on Epilepsy. Target enrollment is 158 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.